NCT04428476View on ClinicalTrials.gov

Open-label Extension of the HOPE-2 Trial

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

13

Participants

Timeline

Start Date

August 5, 2020

Primary Completion Date

February 16, 2022

Study Completion Date

March 31, 2026

Conditions
Duchenne Muscular Dystrophy
Interventions
BIOLOGICAL

Deramiocel (CAP-1002)

Peripheral infusion of 150 million allogeneic cardiosphere-derived cells administered every three months

Trial Locations (5)

45229

Cincinnati Children's Hospital Medical Center, Cincinnati

53226

Children's Hospital Wisconsin, Milwaukee

63110

Washington University, St Louis

80045

Children's Hospital Colorado, Aurora

95817

University of California, Davis, Sacramento

All Listed Sponsors
lead

Capricor Inc.

INDUSTRY